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Although there is an increasing interest for bioactive food protein hydrolysates as valuable
ingredients for functional food and dietary supplement formulations, their potential
applications are hampered by their insufficient stability in physiological conditions. In this
study, an innovative strategy based on nanomaterials was developed in order to increase
the hempseed hydrolysate stability and the anti-diabetic properties, through their
encapsulation into ionic self-complementary RADA16 peptide based-hydrogels. Atomic
force microscope (AFM) morphological analysis indicated that the new nanomaterials
were composed of a nanofibril network, whose increased diameter in respect to
native RADA16 suggests the presence of transient non-covalent interactions among
the RADA16 supramolecular assemblies and the embedded hempseed peptides.
Structural analysis by FT-IR spectroscopy indicated typical β-sheet signatures. The
RADA16-hempseed protein hydrolysate hydrogel was shown to act as a novel dipeptidyl
peptidase IV (DPPIV) inhibitor in different biological assays. Finally, this nanoformulation
was used as a drug delivery system of the anti-diabetic drug sitagliptin, helping to reduce
its dosage and eventually associated side-effects.
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INTRODUCTION
Bioactive peptides are increasingly recognized as valuable ingredients for the formulation of
functional foods and dietary supplements providing useful health benefits (Arnoldi et al., 2015).
They are rarely present in foods as such, whereas in most cases they are encrypted in protein
sequences andmay be delivered by digestion, enzymatic hydrolysis, or fermentation (Nongonierma
et al., 2017). Different biological activities are currently under investigation, in particular, the
hypotensive (Girgih et al., 2014a), hypocholesterolemic (Arnoldi et al., 2015), and hypoglycemic
ones (Lammi et al., 2016b).
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Protein hydrolysates may be obtained either from animal
or plant proteins: in this context, hempseed proteins may
represent an innovative source of bioactive peptides, since this
seed contains more than 25% protein that can be hydrolyzed
in different conditions using either digestive or food grade
enzymes (Aiello et al., 2016). Enzyme/substrate ratios, pH, time,
and temperature influence in a significant way the peptides
release with a direct effect on bioactivity (Aiello et al., 2017;
Zanoni et al., 2017). Only a few research groups are actively
pursuing the biological activity of hydrolyzed hempseed proteins
with specific interests for the antioxidant (Girgih et al., 2011,
2013, 2014b), hypocholesterolemic (Zanoni et al., 2017), and
hypotensive activities (Girgih et al., 2014a; Malomo et al., 2015),
whereas other biologically properties, such as the anti-diabetic
one, have been rarely considered (Nongonierma and Fitzgerald,
2015a).
In this context, dipeptidyl peptidase IV (DPPIV)/CD26 is
considered an interesting anti-diabetic target. This ectoenzyme
(EC 3.4.14.5), ubiquitously expressed on the surface of various
cell types, such as intestinal epithelial cells (Abbott et al., 1994),
cleaves dipeptides from the N-terminus of polypeptides in which
proline is at the penultimate position. A truncated soluble form
of this enzyme, which possesses a similar activity, is also found
in serum. Enhanced serum DPPIV levels and/or activity have
been suggested to be correlated with many metabolic diseases,
such as type 2 diabetes (T2DM), obesity, cardiovascular disease,
and non-alcoholic fatty liver disease (NAFLD) (Röhrborn et al.,
2015; Nargis and Chakrabarti, 2018). This is considered a
promising therapeutic target for glycemic control, because it
plays a key role in glucose metabolism by N-terminal truncation
and inactivation of the incretins glucagon-like peptide (GLP)-1
and gastrointestinal insulinotropic peptide (GIP) that together
are responsible for up to 70% of post-prandial insulin secretion
(Nauck et al., 2004). Since these hormones are rapidly inactivated
by DPPIV (Doupis and Veves, 2008), the inhibition of this
enzyme promotes insulin secretion and reduces glucagon release.
Even though synthetic DPPIV inhibitors are currently
available on the market, several food-derived peptides and
hydrolysates have been identified and found to act as promising
DPPIV inhibitors (Lammi et al., 2016b; Nongonierma et al.,
2018). Having verified that this kind of information was not
available for hempseed peptides, this study’s first aim was to
evaluate the DPPIV inhibitory activities exerted by hempseed
protein hydrolysates obtained by treating hempseed proteins
with trypsin (HT) or pepsin (HP). The activity was assessed
by different complementary methods, in particular an in vitro
commercial test based on the purified enzyme, an in situ assay
on Caco-2 cells, and an ex vivo test on human serum samples.
Although there are experimental evidences that some food-
derived peptidesmay be absorbed at least in part at intestinal level
(Lammi et al., 2016a), their low stability and bioavailability still
remain major concerns for practical applications. These issues,
however, may be overcome by the use of well-designed and
controlled delivery systems (Park, 2014; Lopalco and Denora,
2018). The development of an efficient, biocompatible, and
bio-absorbable release system requires the use of materials
capable of delivering the bioactive compounds in a controlled
manner, such as self-assembling peptide-based hydrogels (SAPs).
SAPs are recognized as useful tools in a broad range of
biomedical and biotechnological applications, ranging from
carriers for drug (Koutsopoulos et al., 2009; Gelain et al., 2010) or
pesticides delivery (Bolat et al., 2018), scaffolds for regenerative
medicine (Pugliese and Gelain, 2017), to actuators for optics
and fluidics (Tao et al., 2017). Usually, SAPs are short peptides
(8–16 residues) containing alternate charged hydrophilic and
hydrophobic amino acids that, upon exposure to physiological
conditions of pH, temperature, or electrolytes, spontaneously
self-organize into interwoven nanofibers with diameters of 10–
20 nm (Pugliese and Gelain, 2017). Peptide hydrogels are easy
to use, biodegradable, non-toxic, non-immunogenic, and non-
thrombogenic. They are generally more biocompatible (Zhang,
2003) than polymeric materials, such as PLLA, PLGA, PCL, and
their degradation products are easily metabolized into natural
amino acids. Moreover, molecular design permits to tailor SAPs
sequences for specific application needs.
Taking all this information into account, the second objective
of the study was to verify whether it was possible to enhance
the stability of hempseed protein hydrolysates by combining
them with the ionic self-complementary peptide RADA16
(i.e., Ac-RADARADARADARADA-CONH2), a well-known and
characterized SAP based-hydrogel (Zhang et al., 1993). This
objective was achieved by performing different experiments
in order to demonstrate the feasibility of this encapsulation
procedure without disturbing the overall stability of the RADA16
cross-β secondary structures, to assess the morphology and
biomechanics of the obtained nanofibers, and to evaluate the
biological activity of these materials on DPPIV.
Finally, since previous literature has shown that interesting
synergistic effects may be observed when milk peptides are
combined with sitagliptin (Nongonierma and Fitzgerald, 2015b),
one of the main DPPIV inhibitors successfully commercialized
as oral drug for the treatment of T2DM, the third objective of the
study was aimed at evaluating the possible synergistic activity of
the RADA16-hemp hydrogels and sitagliptin.
RESULTS AND DISCUSSION
Evaluation of the Inhibitory Activity of HT
and HP Hydrolysates on DPPIV
In order to assess the anti-diabetic properties of HT and HP
hempseed protein hydrolysates, their ability to decrease in vitro
the DPPIV activity was evaluated as a first biochemical approach.
Preliminarily, HT and HP hydrolysates were tested in vitro at
0.5 and 1.0mg mL−1, respectively. Results suggest that HP is
more active at 1.0mg mL−1, whereas HT shows comparable
inhibitory activities at both concentrations (Figure S1). For this
reason, it was decided to carry out all further experiments at
1.0mg mL−1 as the best concentration for both hydrolysates.
Figure 1A clearly indicates that the HT and HP hydrolysates at
1.0mg mL−1 inhibit in vitro DPPIV activity by 17.5 ± 2.7% and
32.0 ± 6.2%, respectively. The fact that the HP hydrolysate is 2-
fold more active than the HT one highlights the importance of
the specificity of the enzyme used to release the peptides from
the parent proteins. The bioactivity of a single peptide is typically
related to its size and amino acid sequence, whereas that of a
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FIGURE 1 | Inhibition of DPPIV activity by HT and HP hydrolysates evaluated
with different methods. (A) HT and HP hydrolysates (1.0mg mL−1 ) inhibit in
vitro the activity of human recombinant DPPIV by 17.5 ± 2.7 and 32.0 ±
6.2%, respectively. (B) HT and HP hydrolysates (1.0mg mL−1) inhibit in situ
the DPPIV activity in non-differentiated human Caco-2 cells by 15.5 ± 1.8 and
by 22.5%, respectively. *p > 0.05; ****p > 0.0001.
protein hydrolysate depends strictly on its total composition,
including inactive and active species and possible synergistic or
antagonist effects (Aiello et al., 2017; Zanoni et al., 2017).
The inhibitory activity of these hydrolysates on DPPIV is in
agreement with those of other food protein hydrolysates (Lacroix
and Li-Chan, 2012). For instance, simulated gastrointestinal
digestion of the intact rice and hemp proteins yielded DPPIV
IC50 values between 1.85 ± 0.34 and 4.50 ± 0.55mg mL
−1,
respectively (Nongonierma and Fitzgerald, 2015a). Moreover,
a hydrolysate of Atlantic salmon skin gelatin generated using
Flavorzyme R© inhibits the DPPIV activity by 45.0% at 5.0mg
mL−1 (Li-Chan et al., 2012), whereas a hydrolysate prepared by
hydrolyzing Japanese rice bran using Umanizyme G R© inhibits
the DPPIV activity with an IC50 value equal to 2.3mg mL
−1
(Hatanaka et al., 2012). It is important to underline that all
these studies have been performed only using an in vitro tool
in which porcine DPPIV is involved. Although the sequence
is highly conserved among mammalian species, human, and
porcine DPPIV enzymes have only an 88% sequence identity and
there are evidences that porcine and human DPPIV differ in their
susceptibility to inhibition by food-derived peptides (Lacroix and
Li-Chan, 2015). Since the inhibition is stronger on the porcine
DPPIV enzyme than on the human one, the usage of the former
to assess the inhibitory effect may lead to an overestimation of
the potency or effectiveness on human DPPIV (Lacroix and Li-
Chan, 2015). This aspect clearly underlines the need to deeply
investigate the DPPIV inhibitory effects of food-derived peptides
not only from a biochemical point of view but also at human
cellular level (Lammi et al., 2018).
Further experiments were therefore performed using a cellular
assay based on non-differentiated human intestinal Caco-2 cells,
which has been recently developed and optimized by us as a
useful tool for the screening and identification of new DPPIV
inhibitors (Lammi et al., 2018). These cells express several
morphological and functional characteristics of enterocytes,
possess a wide range of membrane peptidases naturally expressed
by the apical side of enterocytes, DPPIV included, and are useful
to investigate the potential metabolism of tested compounds.
Caco-2 cells were treated with 1.0mg mL−1 of HT and HP
hydrolysates for 24 h, then the AMC-Gly-Pro substrate (50.0µM)
was added, and the fluorescence signals were detected by a plate
reader. Figure 1B shows that the HT hydrolysate inhibited the
DPPIV activity by 15.5 ± 1.8% and HP hydrolysate by 22.5 ±
0.19%. These results confirm the in vitro tests although they also
indicate that the incubation with the Caco-2 cells slightly impairs
the inhibitory potencies of the hydrolysates, with a greater effect
on the HP one. This may be possibly explained by metabolic
effects.
A very critical issue in the practical application of food
peptides regards the low stability especially in respect to the
proteases present in the biological samples, in particular in
serum. Therefore, ex vivo experiments were also performed
spiking human serum samples with HT and HP hydrolysates
at the concentration of 1.0mg mL−1 and incubating at 37◦C
for 24 h. The next day, the AMC-Gly-Pro substrate (50.0µM)
was added and the fluorescence signals were measured. Small
inhibitory activities were observed in both cases that were not
significant (data not shown), whereas sitagliptin, used as a
positive control, reduced the circulating enzyme activity by 68.5
± 5.3% vs. the control sample. These results are indicative of
an extensive degradation of the hydrolysates in this complex
environment.
This whole body of information prompted us to develop a
new strategy that might overcome the observed limitations and
improve the DPPIV inhibitory activity by incorporating them
within the nanofibrous structures of RADA16 SAP-hydrogel.
Self-Assembly of RADA16-HT and
RADA16-HP Hydrolysates Into Fibrillar
Nanostructures
The ionic self-complementary RADA16 peptide is known to
have a strong propensity to spontaneously self-assemble into
ordered nanofibrous structures upon exposure to external stimuli
(e.g., pH, temperature, monovalent, or divalent electrolyte ions).
Typically, RADA16 fibrils are linear with a 10–20 nm diameter
and a 2.5–5 nm length (Zhang et al., 1993). At the macroscale,
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these nanofibers further organize to form highly hydrated
hydrogels containing up to 99.5% (w/v) water, which can be easily
and harmlessly used as drug delivery systems (Koutsopoulos
et al., 2009; Gelain et al., 2010). To assess whether the hempseed
hydrolysates modify the self-assembly propensity of RADA16,
this material was dissolved in distilled water at the concentration
of 10mg mL−1 and mixed with the HT and HP hydrolysates
(1.0mg mL−1) at a 3:1 (v/v) ratio. In order to further promote
self-assembly, an isotonic saline solution (ionic strength 0.09%)
was slowly added to the mixed peptide solutions, and the
hydrogels were formed at room temperature. The 3:1 ratio
between RADA16 and hempseed peptides was employed, since
the increase of RADA16 concentration resulted in a higher
density network of nanofibers that may possibly hinder the
release of the hempseed peptides, and probably increase the
interactions of RADA16 nanofiber-hemp diffusant yielding a
decrease in apparent diffusivity (Figure 2A).
The freshly prepared RADA16-hemp hydrolysate solutions
were viscous-liquid, clear, and homogeneous (Figure 2B); after
the hydrogelation, the solutions took on a gel-like consistency
and no noticeable aggregates were visualized (Figure 2C).
Atomic force microscope (AFM) morphological analysis, carried
out to monitor the effects of HT and HP peptides on the
self-aggregated nanostructures of RADA16, showed a network
of nanofibrils with ∼24 nm diameter and up to 2 nm length
(Figure 2D), similar to those previously reported (Yokoi et al.,
2005). The slight increase of RADA16-hempseed peptides
diameters from AFM imaging, compared to native RADA16,
suggests the presence of transient non-covalent interactions (i.e.,
electrostatic forces, VDW, hydrogen bonds) among the RADA16
supramolecular assemblies and the embedded hempseed peptides
(see Table S1 in the ESM).
Overall, these AFM results confirmed the assembly propensity
of RADA16-hempseed peptides into nanofibers, highlighting
that HP and HT hydrolysates minimally perturb the RADA16
structures, and therefore they can be easily trapped inside the
entangled nanofibrous domains of the RADA16 hydrogel, which
allows less free motion of the hemp diffusants and facilitate their
slow and sustained release.
Influence of HT and HP Hydrolysates on
Assembled Secondary Structures
Structural analysis of assembled RADA16-hempseed
hydrolysates was pursued by attenuated total reflection
(ATR) Fourier transform infrared (FT-IR) spectroscopy. As
expected, by analyzing the Amide I region (1,600–1,700 cm−1),
which is mainly associated with C=O stretching vibration and
related to the SAP-backbone conformation, native RADA16
showed β-sheet features characterized by the presence of the two
components at 1,630 and 1,695 cm−1 (Figure 3A). FT-IR spectra
of the RADA16-HP hydrolysate and RADA16-HT hydrolysate
closely resembled that of the RADA16 in the native state,
displaying typical β-sheet signatures. Moreover, in the Amide
II region (1,480–1,575 cm−1), β-sheet aggregation for all tested
RADA16-hempseed hydrolysates was confirmed by the presence
of peaks at 1,530 cm−1 (directly related to CN stretching and NH
bending). Altogether, FT-IR analysis confirmed self-aggregation
of tested RADA16-hempseed hydrolysates into β-sheets,
suggesting that the introduction of hempseed hydrolysates did
not affect the macromolecular organization of the RADA16
hydrogel.
Furthermore, to get more information on the RADA16-
hempseed hydrolysates capacity of forming cross-β fibril
structure, thioflavin T (ThT) spectroscopy assay was carried out.
It is widely accepted that β-rich structures feature ThT-binding
sites, and that these interactions may give insights on cross-β
structures and fibril formation (Biancalana and Koide, 2010).
ThT has a weak fluorescence in aqueous environment, with
excitation and emission bands centered at ∼350 and 440 nm,
respectively. Upon binding to β-rich fibrils, bathochromic shifts
of both excitation and emission at 440 and 490 nm, respectively,
are observed. The emission intensity at ∼490 nm is assumed to
be directly proportional to the quantity of cross-β fibrils present
in the sample. When the probe ThT was applied to RADA16,
a characteristic fluorescence emission at ∼490 nm confirmed
that the peptide had adopted a cross-β-sheet conformation
(Figure 3B). Instead, an increase of ThT fluorescence intensity
was found when RADA16 was mixed with either HT or HP
peptides (Figure 3B). This suggested that hempseed peptides
might increase the overall presence of cross-β structures in
self-assembled RADA16 hydrogels, probably due to transient
electrostatic repulsions that can be formed between hempseed
peptides and RADA16 molecules during self-assembly and
nanofiber formation. This shows that electrostatic interactions
could play a pivotal role in the stability of fibrillar systems as
carriers for drug delivery. A reasonable explanation concerning
this behavior has been proposed by Zhang et al. (1993) using
RADA16 hydrogel as a platform to release lysozyme, trypsin
inhibitor, BSA, and IgG (Koutsopoulos et al., 2009). They
speculated that SAPs charge may be an important factor affecting
not only the fibers stability, but also the interactions and release
kinetics when the release occurs through peptide hydrogels
consisting of nanofibers that carry a net (positive or negative)
charge.
Biomechanical Properties of RADA16-HT
and RADA16-HP Hydrogels
In addition to morphological and structural properties, the
biomechanics of the nanostructures play a significant role in
translation for applications (e.g., nano-carriers, nano-devices,
actuators for optics, and fluidics etc.) (Pugliese et al., 2018a,b).
In the case of hydrogels, the most relevant biomechanical
features to be characterized are the storage (G′) and loss
(G′′) moduli. The former reflects the stiffness trend of the
biomaterial, while the latter represents the energy dissipated
during the test and correlates with the liquid-like response of
the hydrogel. The ratio between G′ and G′′ provides insights
of the viscoelastic profile of tested material, i.e., whether it
behaves as a viscous liquid (G′ <G′′) or as an elastic solid
(G′ >G′′). Accordingly, it was crucial to assess the elastic
and viscous response of materials, by varying frequencies of
applied oscillatory stress (see sectionMethods for further details),
in order to investigate how the HT and HP hydrolysates
could influence the mechanical strength of the RADA16
hydrogel. Upon comparing the rheological properties of native
RADA16, and RADA16-HT or RADA16-HP hydrolysates
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FIGURE 2 | Self-assembly of RADA16-hempseed hydrolysates. (A) Cartoon models of RADA16-HT (left) and RADA16-HP (right) peptide based-hydrogels. RADA16
network of nanofibers is shown in purple, while HT and HP are in cyan and dark gray, respectively. (B) Photographs of freshly prepared RADA16–hempseed solution
and (C) after hydrogelation (in 0.09% saline). (D) AFM morphological analysis of RADA16-HT and RADA16-HP hydrogels. Images show a network of nanofibrils with
∼24 nm diameter and up to 2 nm length (Scale bar, 1µm).
FIGURE 3 | Structural and biomechanical properties of RADA16-HT and RADA16-HP hydrogels. (A) ATR-FTIR spectra of RADA16-HT (dark) and RADA16-HP (red)
hydrogels closely resemble that of pure RADA16 (blue), displaying typical β-sheet signature in Amide I (1,600–1,700 cm−1 ) and Amide II (1,480–1,575 cm−1) regions.
(B) ThT emission spectra. Pure RADA16 (blue) showed an affinity for ThT ascribable to the presence of cross-β fibril structures, while RADA16-HT (dark) and
RADA16-HP (red) produced an increase of ThT fluorescence intensity due to transient electrostatic interactions between the peptides and RADA16 molecules during
self-assembly and nanofiber formation. (C) Rheological characterization. Assembled hydrogels were monitored by frequency sweep tests (0.1–100Hz). All tested
materials showed typical hydrogel-like profiles featuring a predominant elastic solid-like behavior (G’), as compared with the viscous component (G”). RADA16-HT and
RADA16-HP showed a slight increase in the G’ values (∼750 and ∼450Pa, respectively) along the tested frequency range compared to pure RADA16 (∼353Pa), but
they still showed strength profiles typical of soft peptide scaffolds.
(Figure 3C), trends of G′ and G′′ for all species showed typical
hydrogel-like profiles, featuring a predominant elastic solid-
like behavior (G′), as compared with the viscous component
(G′′). The G′ and G′′ values remained relatively constant
throughout the test; hence all scaffolds were very resistant
to deformation. Nevertheless, RADA16-HP hydrolysates and
RADA16-HT hydrolysates showed a slight increase in the elastic
shear modulus G′ values (∼450 and ∼750 Pa, respectively)
along the tested frequency range (0.1–100Hz) at low strains
(1%) compared to the native RADA16 (∼353 Pa), although
they still were showing strength profiles typical of soft peptide
scaffolds. This slight increase in the mechanical properties may
be attributed to electrostatic interactions taking place between
hempseed peptides and RADA16 molecules during self-assembly
phenomena that increase the overall presence of β-structures (as
investigated in the previous section). Indeed, it is widely accepted
that in β-sheet-rich SAPs after self-assembly, interactions among
self-assembled fibers lead to increase of G′ values.
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Overall, rheological assays showed that the RADA16 hydrogel
mixed with the hempseed hydrolysates had stable mechanical
features. Also, encapsulation of the hempseed hydrolysates did
not alter the RADA16 self-assembling propensity, displaying
instead a slight improvement in elastic shear modulus G′.
Therefore, on the whole, these results provided insight on
the feasibility of hempseed peptides encapsulation that may
turn in their smart delivery and sustained release from
the nanoformulation, which is an open challenging issue of
nanotechnology in the food and agriculture sectors.
Enhanced DPPIV Inhibitory Activity and
Stability of RADA16-HT and RADA16-HP
Hydrogels
In order to verify the stability and activity of HT hydrolysates
and HP hydrolysates embedded in the RADA16 hydrogel, their
DPPIV inhibitory activities were performed by in situ and ex
vivo experiments. Before performing the in situ experiments,
MTT experiments were performed in order to exclude any
potential cytotoxic effect mediated by the new hydrogels on non-
differentiated Caco-2 cells. These experiments demonstrated that
they are safe at 1.0mg mL−1, i.e., the concentration used for
all biological experiments (Figure S2). After having assessed
this important information, Caco-2 cells were seeded on the
RADA16-HT and HP hydrogels (1.0mg mL−1) and after 24 h
their effects on the DPPIV activity were measured using AMC-
Gly-Pro as a substrate (50µM). Figure 4A shows that RADA16-
HT and RADA16-HP hydrogels reduced the DPPIV activity
by 38.3 ± 5.6 and 42.2 ± 3.0% vs. the RADA16 hydrogel,
respectively. These findings indicate that the activities of the
HT and HP hydrolysates are enhanced by 2.5- and 2.0-folds,
respectively, when they are embedded in the hydrogel in
respect to their plain solutions. This seems to indicate that the
structuring of the HT and HP hydrolysates within the RADA16
hydrogel provides higher resistance toward the proteases that are
expressed by Caco-2 cells. The RADA16-HT and RADA16-HP
hydrogels represent dynamic systems in which some peptides
actively contribute to the biomechanical, morphological, and
structural properties of the nanoformulations, since transient
electrostatic repulsions, between the hempseed peptides and
the RADA16 molecules during self-assembly and nanofiber
formation, can occur. These electrostatic interactions contribute
to the stabilization of the fibrillar systems making them good
carriers for bioactive compounds delivery. The experimental
findings suggest that hempseed peptides, trapped inside the
entangled nanofibrous domains of the hydrogels, are slowly
released allowing their interaction with the DPPIV catalytic
site. In fact, results pointed out that both HT and HP are
released from the hydrogels as a function of time with a linear
trend. In particular, using an experimental method proposed
by Goa (1953) and already used by us (Lammi et al., 2014,
2016a), the released peptide concentrations were measured after
1, 3, and 6 h of incubation. Figure 4B shows that released HT
peptide concentrations were 0.36 ± 0.06, 0.52 ± 0.15, and 0.92
± 0.06 µg µL−1, whereas released HP concentrations were
0.23 ± 0.03, 0.41 ± 0.09, 0.79 ± 0.08 µg µL−1 after 1, 3,
and 6 h, respectively. Overall, HT peptides were more delivered
than HP peptides; this difference may be due to the different
physical-chemical properties of each hempseed hydrolysate. As
reported in Table S1 (see Supplementary Material), the HT
hydrolysate shows a hydrophilicity of 63%, whereas HP peptides
one of 57%. Being more hydrophobic, HP peptides are more
retained within the shell of the hydrogel, whereas the more
hydrophilic HT peptides are more released. Moreover, the HP
hydrolysate contains longer peptides (>15 a.a. residues) than
the HT hydrolysate. This explains why the HT peptides may
more easily escape from the entangled nanofibrous domains of
the hydrogels than HP peptides (Table S1). This slow release
enhanced either the activity or the stability of both HT and HP
hydrolysates.
This hypothesis was also confirmed by ex vivo experiments
performed on human serum samples. More in detail, serum
samples were incubated with either RADA16-HT or RADA16-
HP hydrogels for 24 h at 37◦C. Afterwards, the AMC-Gly-Pro
substrate (50.0µM) was added, and the fluorescence signals
detected using a plate reader. Figure 4C indicates that both
hydrogels are able to decrease the circulating DPPIV activity
by 37.2 ± 2.3 and 36.2 ± 2.6%, respectively, vs. native
RADA16. These results underline the enhanced stability that
hempseed peptides acquire when they are embedded in the
nanoformulations: in fact, both native hydrolysates were unable
to inhibit the activity of circulating DPPIV in the ex vivo system
probably due to their scarce capacity of resisting to the serum
proteases activity.
Synergistic Effect of RADA16-Hempseed
Hydrolysates With Sitagliptin as DPPIV
Inhibitors
The last part of the experimentation was dedicated to
investigating the possible synergist effects of combining
sitagliptin with the RADA16-hempseed hydrogels
(Figures 5A–F) for DPPIV inhibition. RADA16 hydrogels
containing sitagliptin (at the final concentration of 0.1µM)
and RADA16 hempseed hydrogels containing sitagliptin (at
the final concentration of 0.1µM) were prepared and Caco-2
cells were seeded on the hydrogel. After 24 h, the spent medium
was removed, cells were washed, the Gly-Pro-AMC substrate
was added, and the fluorescence signals were monitored for
10min. The results (Figures 5A,B) clearly indicate that at all
reaction times, the DPPIV activity was the highest in the control
samples treated with RADA16-hydrogel, slightly lower in cells
incubated with RADA16 hydrogel containing 0.1µM sitagliptin,
and further reduced in cells incubated with RADA16-HT and
RADA16-HP hydrogels with or without sitagliptin 0.1µM.
However, findings clearly suggest that only RADA16-HT
containing 0.1µM sitagliptin shows a synergistic inhibitory
effect of DPPIV, which started 3min after the addition of the
Gly-Pro-AMC substrate and remained constant for up to 10min
of incubation (Figure 5B). The reaction rate followed a linear
trend and 5min of incubation with Gly-Pro-AMC corresponded
to one half of the linear tract. Figure 5B shows the results at
5min. RADA16 hydrogel containing 0.1µM sitagliptin reduced
the DPPIV activity by 13.2 ± 8.3% vs. RADA16 alone, whereas
the inhibition of the enzyme activity reached 38.3 ± 5.6 and
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FIGURE 4 | DPPIV inhibitory activity, stability, and release of RADA16-HT and RADA16-HP hydrogels. (A) RADA16-HT and RADA16-HP hydrogels (1.0mg mL−1)
reduce in situ the DPPIV activity in non-differentiated human Caco-2 cells by 38.3 ± 5.6 and 42.2 ± 3.0%, respectively, vs. the RADA16 hydrogel. (B) Release of HT
and HP peptides from the RADA16 hydrogel as a function of the time. (C) RADA16-HT and RADA16-HP hydrogels decrease the circulating DPPIV activity ex vivo on
human serum samples by 37.2 ± 2.3 and 36.2 ± 2.6%, respectively, vs. plain RADA16. **p > 0.01.
42.2 ± 3.0%, respectively, incubating with control RADA16-HT
and RADA16-HP hydrogels, and 56.4 ± 0.8 and 40.0 ± 9.1%,
respectively, incubating with RADA16-HT and RADA16-HP
hydrogels containing 0.1µM sitagliptin.
From a nanostructural point of view, the addition of sitagliptin
did not affect the physicochemical properties of the RADA16-HT
and RADA16-HP hydrogels. The ATR-FTIR structural analysis
highlighted typical β-sheet signatures in the Amide I and
Amide II regions (Figure 5C) and the ThT spectroscopy assay
confirmed the cross-β-sheet conformation of both hydrogels
in the presence of sitagliptin (Figure 5D). In the same way,
frequency sweep tests of the resulting RADA16-HP-sitagliptin
and RADA16-HT-sitagliptin hydrogels revealed elastic moduli of
486 and 1,028 Pa, respectively (Figure 5E), indicating that they
still maintain viscoelastic profiles similar to those of RADA16-
HT and RADA16-HP samples. Lastly, an insight of the RADA16
nanofibers bundles formation trapped with hempseed peptides
and sitagliptin is provided through a cartoon model as depicted
on Figure 5F.
In summary, these results underline one important aspect,
namely that RADA16-hempseed hydrolysates hydrogels are not
only good sitagliptin delivery carriers, but are also active as
DPPIV inhibitors suggesting that the combination of sitagliptin
with food protein based hydrogels may help reducing drug
dosage and their potential side-effects.
CONCLUSION
This work offers a new route for the formulation of nano-
nutraceuticals entirely made of biocompatible/bioabsorbable
SAP based-hydrogels and bioactive hydrolysates to be exploited
in diabetes and metabolic diseases prevention.
METHODS
Materials
Fmoc-Arg(Pbf)-OH, Fmoc-Ala-OH, and Fmoc-Asp(OtBu)-
OH were purchased from the Aapptec (Louisville, USA)
and used as received. N,N-dimethylformamide (DMF), N,N-
diisopropylethylamine (DIPEA), N-methyl-2-pyrrolidone
(NMP), trifluoroacetic acid (TFA) and triisopropylsilane were
purchased from VWR (Radnor, USA). N,N,N′,N′-tetramethyl-
O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate
(HBTU), 1-hydroxybenzotriazole hydrate (HoBT), 4-
metylpiperidin and Thioflavin T were purchased from
Sigma-Aldrich. HPLC grade water (resistivity 18 MΩ cm)
and DPBS (pH 7.4) were purchased from Thermo Fisher
scientific (Waltham, USA).
Production of HT and HP Hydrolysates
HT and HP hydrolysates were obtained extracting the proteins
from the seeds of Cannabis sativa cultivar Futura, by hydrolyzing
them with pepsin or trypsin and by analyzing them as described
elsewhere (Aiello et al., 2017; Zanoni et al., 2017).
In vitro DPPIV Activity Assay
The experiments were carried out using a procedure previously
reported (Lammi et al., 2018). Briefly, 0.5 and 1.0mg mL−1
of HT and HP hydrolysates were tested in vitro using
the purified recombinant DPP-IV enzyme and fluorescent
substrate (AMC-Gly-Pro, ex/em 360/465 nm). Fluorescence
signals were measured using the Synergy H1 from Biotek (Bad
Friedrichshall, Germany). More details are reported in the
Supplementary Materials.
Cell Culture
Caco-2 cells, obtained from INSERM (Paris), were cultured
at 50% density following the procedure previously reported
(Lammi et al., 2018). More details are reported in the
Supplementary Materials.
In situ DPPIV Activity Assay
HT and HP hydrolysates were tested on Caco-2 cells (5 ×
104/well in black 96-well plates) at 1.0mg mL−1 or vehicle
in growth medium for 24 h at 37◦C, following the method
previously optimized and reported (Lammi et al., 2018). For 2D
cell culture on RADA16-HT and RADA-HP hydrogels, Caco-
2 cells were seeded on the surface of the above mentioned
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FIGURE 5 | Synergistic effect of RADA16-hempseed hydrolysates with sitagliptin as DPPIV inhibitor in the Caco-2 cells. (A) Kinetics of the degradation of substrate
Gly-Pro-AMC catalyzed by DPPIV. In respect to the control sample (RADA16-hydrogel), the DPPIV activity is slightly decreased when Caco-2 cells are incubated with
RADA16 hydrogel containing 0.1µM sitagliptin and it is much more reduced when cells are treated with either RADA16-HT or RADA16-HP hydrogels with or without
0.1µM sitagliptin. (B) DPPIV activity after incubating Caco-2 cells with different hydrogels (at 5min). The RADA16 hydrogel containing 0.1µM sitagliptin reduced the
DPPIV activity by 13.2 ± 8.3% vs. pure RADA16, whereas RADA16-HT and RADA16-HP alone drop the enzyme activity by 38.3 ± 5.6 and 42.2 ± 3.0%, respectively.
RADA16-HT and RADA16-HP containing 0.1µM sitagliptin reduced the enzyme activity by 56.4 ± 0.8 and 40.0 ± 9.1%, respectively. (C,D) Structural properties of
RADA16-HT-sitagliptin (cyan) and RADA16-HP-sitagliptin (magenta) hydrogels. The ATR-FTIR structural analysis highlighted typical β-sheet signature in the Amide I
and Amide II regions. ThT spectroscopy assay confirmed the cross-β-sheet conformation of both hydrogels in presence of sitagliptin. (E) Rheological characterization
of RADA16-HT-sitagliptin and RADA16-HP-sitagliptin hydrogels monitored by frequency sweep tests (0.1–100Hz) revealed elastic moduli of 1,028Pa and 486Pa,
respectively. Both samples maintained viscoelastic profiles similar to those of RADA16-HT and RADA16-HP hydrogels along the tested frequency range at low strains
(1%). (F) Cartoon models of RADA16-HT-Sitagliptin (left) and RADA16-HP-Sitagliptin (right) peptide based-hydrogels. RADA16 network of nanofibers is shown in
purple, HT peptides in cyan, HP peptides in dark gray and sitagliptin is shown as spheres representation. **p > 0.01.
hydrogels at the density of 5× 104/well; on the day after the spent
media were removed and cells were washed with 100 µL of PBS
without Ca++ and Mg++, and 100 µL of DPPIV substrate at the
concentration of 50.0µM in PBS without Ca++ and Mg++ were
added in each well. Fluorescence signals (ex./em. 350/450 nm)
were measured using the Synergy H1 from Biotek every 1min
for 10min.
Ex vivo DPP-IV Activity Assay
A volume of 40 µL of serum samples was loaded in each
well of the black 96-well plates and 10 µL of the 5 × HT
and HP hydrolysates were spiked in order to have the final
concentration of 1.0mg mL−1 in the total volume of 50 µL.
For hydrogel experiments, 40 µL of human serum samples were
incubated with RADA16-HT and RADA-HP. Samples were then
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incubated for 24 h at 37◦C. Subsequently, 50µL of the AMC-Gly-
Pro at the initial concentration of 100µM were added in each
well in order to obtain the final 50µM substrate concentration
in the final volume of 100 µL. Fluorescence signals (ex./em.
350/450 nm) were measured using the Synergy H1 every 1min
for 10min.
Determination of HT and HP Peptides
Release From the Hydrogels
The peptide leaking from the hydrogels as a function of time
was measured according to a method previously described (Goa,
1953; Lammi et al., 2016a). Briefly, a sterile solution of peptone
from casein at 10mg mL−1 in water was prepared and used as
standard for the calibration curves. Thus, a solution of X µL of
HT and HP peptides contained in the hydrogels after 1, 3, and
6 h of incubation and/or peptone mixture, (100 – X) µL water,
95 µL 6% (w/w) NaOH in water, and 9.5 µL of active reagent
(containing 0.6M sodium citrate, 0.9M sodium carbonate, and
0.07M copper sulfate, 2.4M NaOH, pH 10.6) was prepared.
The reaction mixture was incubated for 15min at RT and the
absorbance was measured at 330 nm using the Synergy H1 plate
reader.
Peptide Synthesis and Purification
RADA16 was synthesized by solid-phase Fmoc-based chemistry
on Rink amide 4-methyl-benzhydrylamine resin (0.5 mmol g−1
substitution) using the Liberty-Discovery (CEM) microwave
automated synthesizer (Matthews, USA), as previously described
(Gelain et al., 2010).
Assembly of RADA16 Embedded With
Hemp-Protein Hydrolysates
The purified RADA16 was dissolved at 10mg mL−1 in distilled
water, sonicated for 30min, and incubated at 4◦C for 24 h. HT
and HP hydrolysates were dissolved at 1.0mg mL−1 in distilled
water. Sitagliptin was used at a final concentration of 0.1µM. The
RADA16 solution was then mixed with HT and HP solutions at a
ratio of 3:1 (v/v), whereas RADA16 was mixed with the solution
containing both hempseed hydrolysates and sitagliptin at a final
ratio of 3:0.5:0.5 (v/v).
Spectroscopic Analysis
FT-IR analysis of assembled nanostructures was performed
on peptides dissolved at a concentration of 1% (w/v) in
distilled water, after 24 h incubation at 4◦C. All spectra were
collected in attenuated total reflection (ATR) using Perkin
Elmer Spectrum 100 spectrometer. All the collected spectra
were reported after ATR correction, smoothing, and automatic
baseline correction using OriginTM8 software. Each sample was
analyzed in triplicate. In order to assess the presence of cross-β
fibril structures, ThT binding assay was monitored by exciting the
sample at 440 nm (5 nm band-pass) and recording the emission
fluorescence spectrum from 460 to 600 nm.
Rheological Tests
Rheological properties of assembled nanostructures were carried
out using a controlled stress AR-2000ex Rheometer (TA
instruments). A truncated cone-plate geometry (acrylic truncated
diameter, 20mm; angle, 1◦; truncation gap, 34µm) was used.
All measurements were obtained at 25◦C using a Peltier cell
as a lower plate of the instrument to keep the temperature
controlled during each test. All samples were tested 1day
after dissolution at the concentration of 1% (w/v). Frequency
sweep experiments were recorded as a function angular
frequency (0.1–100Hz) at a fixed strain of 1%. Strain sweeps
were performed on samples from 0.01% to a maximum
strain of 1,000% for determining the limit of the linear
viscoelastic region and the maximum strain to which the
sample can be subjected. Each experiment was performed in
triplicate.
Atomic Force Microscopy
AFM tests were performed in tapping mode by a Multimode
Nanoscope V (Digital Instrument, Veeco), using a single-
beam silicon cantilever probes (Veeco RFESP MPP-21100-10,
cantilever f0, resonance frequency 59–69KHz, constant force 3N
m−1), as previously described (Pugliese et al., 2018a).
Statistical Analysis
Statistical analyses were carried out by t-student and One-way
ANOVA using Graphpad Prism 6 (Graphpad, La Jolla, CA, USA)
followed by Dunnett’s test. Values were expressed as means± SD;
P < 0.05 were considered to be significant.
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